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Abstract
Purpose: Following radical nephroureterectomy for upper urinary tract urothelial carcinoma (UTUC), intravesical recurrence (IVR) is
found in 22% to 47% of patients. Patients with a primary urothelial carcinoma of the bladder (UCB) have an increased risk of a future
UTUC (1%−5%). Paired UTUC and UCB might represent clonally related tumors due to intraluminal seeding of tumor cells or might be
separate entities of urothelial carcinoma caused by field cancerization. We systematically reviewed all the relevant literature to address the
possible clonal relation of UTUC and paired UCB. Materials and Methods: MEDLINE, EMBASE, and COCHRANE databases were sys-
tematically searched for relevant citations published between January 2000 and July 2019. This study was performed according to the Pre-
ferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Of 5038 citations identified, 86 full papers were screened,
and 9 studies met the inclusion criteria. Results: The populations studied and the molecular techniques used to assess clonality of UTUC
and paired UCB differed largely over time. Eight studies reported on primary UTUC and meta- or synchronous IVR without a history of
UCB. A total of 118 tumors (55 UTUC and 63 IVR) from 49 patients were included, of which 94% seemed to be clonally related. Five stud-
ies reported on primary UCB and subsequent UTUC with a total of 61 tumors (30 UCB and 31 UTUC) from 14 patients; a possible clonal
origin was identified for 85% of the tumors. Conclusion: Taking into account the limitations of microsatellite technology in comparison to
Next Generation Sequencing and currently accepted concepts of tumor heterogeneity and evolution, this systematic review shows that
most, if not all, UTUC and paired UCB likely are clonally related.  2020 The Author(s). Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords: Bladder carcinoma; Clonality; Intravesical recurrence; Upper urinary tract; Urothelial carcinoma1. Introduction
Urothelial carcinomas can arise throughout the entire
urinary tract, but the urinary bladder is the predominant
side of origin. The incidence of upper urinary tract urothe-
lial carcinoma (UTUC) is 1 to 2 per 100,000 persons/year*Corresponding author. Tel.: +31 107040704.
E-mail address: t.vandoeveren.1@erasmusmc.nl (T. van Doeveren).
https://doi.org/10.1016/j.urolonc.2020.01.008
1078-1439/ 2020 The Author(s). Published by Elsevier Inc. This is an open acce
(http://creativecommons.org/licenses/by-nc-nd/4.0/)in Western Europe, and UTUC accounts for 5% to 10% of
all urothelial carcinomas [1]. UTUC and urothelial bladder
cancer (UCB) are considered similar entities. Accordingly,
results of studies on UCB are often extrapolated to UTUC.
Although UCB and UTUC share certain histopathological
characteristics and have several risk factors in common,
with tobacco use as the most imperative one, important
clinical and molecular differences exist between the 2 enti-
ties [2]. At diagnosis, 60% of UTUC patients have anss article under the CC BY-NC-ND license.
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Hence, the prognosis of UTUC is poor with a 5-year overall
survival (OS) of approximately 70%; for invasive disease
the 5 year OS is less than 40%, which is lower than reported
for UCB patients treated with radical cystectomy [4,5].
Recent genomic characterization of UTUC revealed dif-
ferent molecular alterations in comparison to UCB and, in
contrast to UCB, UTUC seemed to be associated with
Lynch syndrome (LS) [6−8].
Following radical nephroureterectomy (RNU), which is
the recommended treatment for nonmetastatic UTUC, intra-
vesical recurrence (IVR) within the first 2 years following
surgery is found in 22% to 47% of the patients [1,9,10]. Clin-
ical risk factors for the development of an IVR following
RNU are: a history of UCB, tumor multiplicity, tumor loca-
tion (distal ureter), advanced tumor stage, and the operative
modality [11]. Guidelines recommend administration of a
single dose of intravesical chemotherapy within 10 days after
RNU to reduce the risk of a future IVR [1,12,13]. A neoadju-
vant regimen of intravesical Mytomicin C is being evaluated
in an ongoing multicenter study [14].
UTUC patients also have an increased risk of developing
a tumor in the contralateral upper urinary tract; 2%to 6%
develop a recurrence in the contralateral upper urinary tract
following RNU [15]. Moreover, the incidence of concomi-
tant UCB at the time of diagnosis of primary UTUC is 17%
[16], whereas the risk of developing an UTUC following
the diagnosis of a primary UCB is much lower. In a cohort
of 1,529 patients with primary nonmuscle invasive UCB,
the incidence of a subsequent UTUC was only 2.6%,
although the proportion was higher in multifocal and high-
risk tumors [17]. In summary, urothelial carcinoma is an
important risk factor for developing a subsequent tumor
throughout the entire urinary tract; patients with a primary
UTUC have the highest risk of developing a recurrence in
the bladder.
Two hypotheses have been proposed for the increased risk
of recurrence in the urinary tract following a primary diagno-
sis of urothelial carcinoma. One hypothesis is that the entire
urinary tract is affected by carcinogenic hits [18], which
results in multifocal tumors that develop independently from
one another. These tumors are therefore thought not to share
the same progenitor cell. However, this would not explain
the difference in incidence of UTUC and UCB in general,
nor the difference in incidence of tumors in the contralateral
urinary tract vs. the bladder after a primary diagnosis of
UTUC. The second hypothesis states that by intraluminal
seeding or intraepithelial spread, tumor cells located in the
upper urinary tract implant in the bladder and give rise to a
recurrence [19,20]. In the latter, IVR will be of monoclonal
origin as it arises from the antecedent UTUC. This hypothe-
sis seems plausible taking into account the low incidence of
UTUC and hence the chance that a patient would develop
2 or more tumors that derive in different parts of the urinary
tract is very low [21,22]. In 2002, a review concluded that
the majority of the studies investigating the clonalrelationship of multiple urothelial carcinomas of the urinary
tract revealed tumors to be of monoclonal origin [23].
We present the results of a systematic review of all the rele-
vant and recent literature addressing whether synchronous and
metachronous urothelial carcinoma of the upper urinary tract
and bladder are clonally related.
2. Materials and methods
The electronic databases Medline (Ovid) and Embase, the
Cochrane Central Register of Controlled Trials, and the
Cochrane Database of Systematic Reviews were searched
for citations published between January 2000 and July 2019.
The review was performed according to the Preferred
Reported Items for Systematic Reviews and Meta-analysis
statement [24] and the protocol has been published in the
PROSPERO database (CRD42018105617).
Original studies that performed a genomic characterization
of UTUC and paired IVR (i.e. both tumors diagnosed in the
same patient) were included, whereas studies that reported on
a molecular analysis of UTUC and UCB samples not derived
from the same patient were excluded (see Fig. 1). Keywords
arranged in variable combinations included “upper urinary
tract urothelial carcinoma,” “intravesical recurrences,”
“ureter,” “renal pelvis,” bladder urothelial carcinoma,”
“clonality,” and “molecular genetics” (see Supplementary
Materials for details of the search strategy). The search was
complemented by cross-referencing of the studies included.
Two reviewers (T.v.D. and J.L.B.) independently screened
all abstracts and full-text articles. Disagreement was
resolved by discussion, and if no agreement was reached, a
third independent party acted as arbiter (E.C.Z.).
2.1. In- and exclusion criteria
Studies with UTUC patients who developed a subsequent
IVR and studies with UCB patients who developed a subse-
quent UTUC were included. Studies that reported on patients
who had recurrences limited to either the upper or lower uri-
nary tract were excluded. At least 1 genomic alteration had
to be present in 1 of the 2 paired tumors of a patient in order
to be included in the final analysis.
2.2. Definition of a clonal relationship between UTUC and
paired UCB
Monoclonal origin: Tumors were considered to be of
clonal origin when both the UTUC and paired UCB shared
synonymous/non-synonymous or noncoding somatic muta-
tions, microsatellite instability (MSI), methylation and Loss
of Heterozygosity (LOH). These molecular alterations had to
be identical in expansion or deletion. An interface of 100%
between the alterations of the 2 tumors was not considered
mandatory since subclones derived from the primary tumor
can expand in the number of alterations independently over
time. A single concordant alteration, pattern of methylation,
Fig. 1. PRISMA flow diagram of the study.
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ation Sequencing (NGS), bisulfate sequencing, or Whole
Exome Sequencing (WES), was considered determinative for
a clonal relationship or a shared progenitor cell, as these
techniques permit to approach the exact gene position of an
alteration. The possibility that a shared molecular alteration
alters on the exact same gene position in 2 analyzed tumors
of the same patient was considered to be negligible, especially
in ‘passenger genes’ [25].
Undefined clonal origin: In case of absence of concor-
dant molecular alterations, we marked the paired tumors
as ‘undefined’ and not of ‘oligoclonal origin’. We chose to
do so as for the analysis we were dependent on the (some-
times limited) number of markers/loci analyzed in the
studies included. Theoretically, it could be possible that
both tumors did share a progenitor cell and were clonallyrelated but that the specific examined marker(s) did not
cover that specific alteration. In those cases, it was not
possible to exclude clonality and, as such, tumors were
classified as ‘undefined’.
It is important to stress that the determination of clonal
relatedness by the aforementioned definitions in some cases
differed from the original authors’ conclusions, which dis-
crepancy might lead to a different assessment of clonally
related tumors.2.3. Definition of synchronous UTUC and UCB
A synchronous recurrence was defined if both tumors,
either UTUC or UCB, were diagnosed within 3 months
following the diagnosis of the primary tumor.
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The large variety of techniques used to analyze clonality
of UTUC and paired UCB precluded a formal meta-analysis.
All patients were considered to share equal weight in the
final analysis, i.e., a patient with multiple recurrences should
have the same contribution to the analysis as a patient with
only 1 recurrence. To do so, the contribution of a patient for
the final analysis was calculated as follows:
patients contribution ¼ 1
n
¢ nc
In which n is the number of recurrences and nc is the
number of clonally related recurrences.
For example: the contribution to the final analysis of a
patient who had 5 recurrences (n = 5), of which 4 (NC = 4)
were clonally related to the primary tumor, was considered
0.8.
patients contribution ¼ 1
5
x 4 ¼ 0:8
The final percentage of clonally related tumors per study
was calculated with the formula:
percentage clonally related tumors ¼
P
nc
N
¢ 100%
In which N is the total number of patients from a study
and
P
nc is the sum of all clonal contributions of all
included patients of that study.3. Results
After removal of duplicates, titles and abstracts of 5,038
records identified in the initial search were screened for rele-
vance. In total, 4,951 abstracts were excluded because the
inclusion criteria were not met. Eventually, 86 full-text
papers were evaluated and 9 studies met the inclusion criteria
(see Fig. 1). Forty-six of the 78 studies that were excluded
performed a genomic characterization of either UCB or
UTUC without a comparison between the 2 entities; 7 studiesTable 1
Study characteristics of the series that analyzed a possible clonal relationship of U
Year Study design Number of p
Takahashi et al. [27] 2000 Case report 1
Dalbagni et al. [28] 2001 Retrospective 13
Hafner et al. [29] 2001 Retrospective 19
Takahashi et al. [30] 2001 Pro- and retrospective 15
Catto et al. [31] 2006 Prospective 9
Warrick et al. [32] 2010 Retrospective 1
Wang et al. [33] 2013 Retrospective 5
Du et al. [34] 2017 Retrospective 3
Audenet et al. [35] 2018 Prospective 29
Abbreviation: UC = urothelial carcinoma.
aLocation in urinary tract not specified.focused on prognostic molecular markers; 11 records were
reviews; 11 studies did not include any genomic analysis;
and 3 studies analyzed unpaired cohorts of UCB and UTUC.
Furthermore, a publication by Jones et al. was excluded from
the analysis because information on the site of origin in
the urinary tract and the timing of tumor development was
lacking [26]. See Table 1 for an overview of the 9 studies
included in this review.3.1. Primary UTUC and subsequent UCB
Eight of the 9 studies included patients who had a primary
UTUC and a meta- or synchronous IVR without a history of
UCB (see Table 2). Since some patients developed more
than 1 UTUC and/or IVR, a total of 118 (55 UTUC, 63 IVR)
tumors from 49 patients were included in the analysis
(Supplementary information Figure S1). The paired tumors
had been analyzed for clonality by various techniques,
which had changed over time. In total, 93.5% of the
patients had concordant patterns of molecular alterations,
indicating that a large proportion of IVR and UTUC were
of monoclonal origin [27−31,33−35].
Takahashi et al. (2000) analyzed 1 case of primary
UTUC and IVR for microsatellite shifts and LOH of chro-
mosomes 2, 4, 8, 9, 11, and 17 using 21 markers [27]. Each
tumor showed LOH of chromosomes 9q and 17p, and the
IVR had additional LOH of chromosomes 2q, 4p, and 11p
(Fig. S1, patient #1). These tumors were considered to be of
clonal origin.
Dalbagni et al. assessed mutations of the TP53 gene in
4 patients who had 16 tumors (5 UTUC, 11 IVR) [28]. All
tumors showed identical mutations of TP53 and thus the
paired tumors were considered to be of monoclonal origin
(Fig. S1, patient # 2−#5). Hafner et al. assessed mutations
in TP53 exons 5 to 9, LOH of chromosome 9, MSI at 6
loci, and protein expressions of hMLH1 and hMSH2 in 15
patients [29]. This study only reported data on a patient
considered not to have clonally related paired tumors; con-
sisting of 1 UTUC followed by 3 IVRs. The UTUC had
loss of the short allele of D9S113, whereas the IVRs hadTUC and IVR/UCB (n = 9)
atients Paired UTUC-UCB samples Number of tumors
Yes 1 UTUC, 1 UCB
Yes 11 UTUC, 39 UCB
Yes 6 UTUC, 16 UCB a72 UC
Yes 16 UTUC, 18 UCB
Yes 12 UTUC, 20 UCB
Yes 3 UTUC, 2 UCB
Yes 6 UTUC, 6 UCB
Yes 10 UTUC, 4 UCB
Yes 29 UTUC, 29 UCB
Table 2
Overview of the studies that analyzed patients diagnosed with a primary UTUC and who subsequently developed a UCB, the molecular techniques used, and
the proportion of clonally related tumors (n = 49 patients)
Patients (n) Number of
tumors (n)
Median months to
recurrence (range)
Target/Technique Number of patients
with clonally related
tumors
Percentage
clonally
related (%)
Takahashi et al., 2000 [27] 1 1 UTUC, 1 IVR 8 LOH (MSI markers): chromosome
9p, 9q, 11p, 17p, 4p, 4q, 2q, 8p;
1/1 100%
Dalbagni et al., 2001 [28] 4 5 UTUC, 11 IVR 14.5 (1−38) TP53 (exons 5-8). 4/4 100%
Hafner et al., 2001 [29] 1 1 UTUC, 3 IVR NA LOH (chrom 9);
p53 (exons 5−9);
MSI (six loci);
IHC (MLH1, MSH2).
0/1 0%
Takahashi et al., 2001 [30] 13 14 UTUC, 16 IVR 9.0 (0−28) LOH (MSI markers): chromosome
9p, 9q, 11p, 17p, 4p, 4q, 2q, 8p;
12/13 92.3%
Catto et al., 2006 [31] 5 7 UTUC, 6 IVR 23.4 (0−47) MSI-H;
Methylation promoter regions:
hMLH1, p16, p14, E-cadherin,
RARB, RASSF1A, MINT31.
5/5 100%
Wang et al., 2013 [33] 5 5 UTUC, 5 UCB NA LOH (9q21, 9q32, 9q22);
TP53 (17p13).
5/5 100%
Du et al., 2017 [34] 3 5 UTUC, 4 IVR 0 WES;
Somatic variants;
Copy number;
Mutational signature.
1.8a/3 60.0%
Audenet et al., 2018 [35] 17 17 UTUC, 17 IVR 22.1 (3-87.8) MSK-IMPACT (NGS). 17/17 100%
Abbreviations: LOH = loss of heterozygosity; MSI = microsatellite instability (H = high); MSK-IMPACT =Memorial Sloan Kettering Cancer Center
integrated mutation profiling of actionable cancer targets (275−468 genes); WES = whole exome sequencing.
a 4 of the 5 (80%) tumors from one patient showed a clonal origin.
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also had identical alterations of TP53, which were not pres-
ent in the UTUC. Therefore, we could not consider these
tumors as clonally related and were therefore scored as
‘undefined’ (Fig. S1, patient #6).
Catto et al. combined MSI analysis using 17 markers
together with methylation of 7 promoter regions [31]. MSI
analysis was performed in 210 patients; only 9 patients had
a UTUC and an IVR showing MSI. Five of these 9 patients
had a primary UTUC followed by 1 or multiple IVR(s). All
paired tumors of these 5 patients shared at least 1 identical
alteration of the methylation markers or had a similar pat-
tern of MSI indicating a clonal relationship (Fig. S1, patient
#20−#24).
In a second study by Takahashi et al. (2001), which used
identical markers as in the 2000 study, a total of 14 UTUC
patients who developed 16 IVRs were analyzed [30] (Fig.
S1, patient #7−#19). Only 1 patient seemed to have discor-
dant molecular alterations; the primary UTUC showed no
alterations in the analyzed markers, while the 2 IVRs had
LOH of a marker on chromosome 11p (Fig. S1, patient
#17). Therefore, we considered the clonal relationship of
the paired tumors as ‘undefined’.
Wang et al. analyzed paired tumors of 5 patients by
3markers for LOH of chromosome 9 and exons 5 to 8 of the
TP53 gene [33] (Fig. S1, patient #25−#29). All 5 paired
samples showed identical patterns of chromosomal loss or
TP53 mutations. One patient, however, had an identicalpattern of TP53 and D9S303, with a complete loss of
D9S171 in the UTUC. Conversely, the IVR only had a loss
of the shorter allele (Fig. S1, patient #26). It is possible that
tumor cells of the primary tumor had seeded or migrated to
the bladder in the possession of LOH of the shorter allele of
D9S171. Due to evolution, the UTUC might have lost
the other allele, contributing to a discordant pattern of this
marker between the 2 tumors. However, an identical LOH
pattern is considered an indication of clonality [23], whereas
identical point mutations in the TP53 gene are considered
even a stronger indication because many possible point
mutations exist that lead to inactivation of TP53. Hence, we
concluded that all tumors were clonally related (Fig. S1,
patient #25−#29).
Du et al. analyzed by whole exome sequencing (WES)
3 cases: 1 female patient had 3 synchronous UTUCs and
2 IVRs; the other 2 patients each had 1 UTUC and 1 IVR
[34] (Fig. S1, patient #30−#32). The 3 UTUCs and 1 IVR
shared the same alterations in TP53, BRAF, and APC genes.
The other IVR had a mutation inMTOR and shared no altera-
tions with the other tumors, so there was no proof of clonality
(Fig. S1, patient #31). One of the 2 other patients showed a
clonal relationship of both tumors (Fig. S1, patient #32). The
other patient showed no shared alterations and, since Du
et al. used WES, this is a strong indication that these tumors
were not clonally related (Fig. S1, patient #30).
Audenet et al. applied NGS with the targeted 230 to 468-
gene MSK-IMPACT oncopanel to analyze primary UTUCs
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All paired tumors had identical point mutations, which is a
strong indicator of monoclonal origin as the chance that
identical point mutations develop independently is highly
unlikely. Comparing the somatic mutations between the
initial UTUC and the subsequent IVR revealed that 86%
of the mutations were present in both tumors. Hence, the
additional mutations of the IVR were presumably caused
by ongoing tumor evolution (Fig. S1, patient #33−#49).
3.2. Primary UCB and subsequent UTUC
Five of the studies included evaluated the possible
clonal relationship in patients diagnosed with primary
UCB who subsequently developed a recurrence in the
upper urinary tract. Since some patients developed more
than 1 UCB and/or UTUC following the primary diagnosis
of UCB, a total of 14 patients having 30 UCBs followed by
31 UTUCs (see Table 3) were included. A total of 85.1%
of the tumors were considered to be of monoclonal origin
[29−32,35].
In 4 of the studies, which included 11 patients with 19
UCBs and 15 UTUC recurrences, all tumors originating
from 1 patient had identical alterations, indicating a mono-
clonal origin [30−32,35]. The studies by Catto et al.,
Takahashi (2001) et al. and Audenet et al. are discussed in
Section 3.1 above [30,31,35]. The techniques used to ana-
lyze a clonal relationship did not differ for patients having
a primary UCB and a subsequent UTUC. These 3 studies
showed all paired tumors to be of monoclonal origin (Fig.
S2, patient #4−#6 and #8−#14).
Warrick et al. included 1 patient having 1 UCB and
3 UTUC and found with the use of NGS identical mutationsTable 3
Overview of the studies that analyzed patients diagnosed with a primary UCB and
the proportion of clonally related tumors (n = 14 patients)
Patients (n) Number of
tumors (n)
Median months
recurrence (rang
Hafner et al., 2001 [29] 3 11 UCB, 5 UTUC 24 (0−43.0)
Takahashi et al., 2001 [30] 1 5 UCB, 3 UTUC NI
Catto et al., 2006 [31] 2 6 UCB, 2 UTUC 17.0 (0−31.0)
Warrick et al., 2015 [32] 1 1 UCB, 4 UTUC 0
Audenet et al., 2018 [35] 7 7 UCB, 7 UTUC 7.3 (3.9−21.7)
Abbreviations: CNV = copy number variations, IHC = immunohistochemistry,
a 12 of the 13 (92%) tumors from 1 patient showed a clonal origin.in the genes HRAS, FLT4, MLL2, NTRK3, and PIK3CA
[32]. Copy number analysis and LOH revealed a compatible
pattern of gain and loss between the paired tumors (Fig. S2,
patient #7).
Hafner et al. included patients having 1 or multiple
UCB(s) followed by 1 or more UTUC [29]. Two patients
had 1 UCB with 1 subsequent UTUC and both tumors
could not be defined as clonally related (Fig. S2, patient
#1 and #2). The other patient had multiple urothelial carci-
nomas, i.e., 9 UCBs with 3 subsequent UTUCs (Fig. S2,
patient #3). Clustering, based on the reported molecular
markers, showed that multiple UTUC and UCB shared
common alterations and these were therefore marked as
clonally related (Fig. S3). One UCB had a distinct pattern
of alterations, however, and was marked as ‘undefined’.
4. Discussion
We conducted a systematic review of the relevant liter-
ature on the possible clonal relation of synchronous and
metachronous urothelial carcinoma of the upper urinary
tract and bladder. Based on the available literature, we
concluded that the majority of UTUC and paired UCB had
a clonal relation. Literature on this matter, however, was
scarce and the techniques used differed significantly
between series and over time. Some of the techniques used
are nowadays considered less accurate to address a possi-
ble clonal relation of 2 tumor entities. Conversely, cur-
rently available large-scale sequencing techniques such as
NGS or Whole Genome Sequencing can much better pro-
vide profound evidence whether paired UTUC and UCB
samples are of monoclonal origin, as the probability that
point mutations occur multiple times independently fromwho subsequently developed a UTUC, the molecular techniques used, and
to
e)
Target/Technique Number of
patients with
clonally related
tumors
Percentage
clonally
related (%)
LOH (chrom 9)
TP53 (exons 5-9)
MSI (six loci)
IHC (MLH1, MSH2)
0.92a/3 30%
LOH (MSI markers): chromosome
9p, 9q, 11p, 17p, 4p, 4q, 2q, 8p;
Subchromosomal breakpoints.
1/1 100%
MSI-H;
Methylation: hMLH1, p16, p14,
E-cadherin, RARB, RASSF1A,
MINT31.
2/2 100%
NGS (409 genes);
LOH;
CNV.
1/1 100%
MSK-IMPACT (NGS). 7/7 100%
NGS = next generation sequencing, NI = not informative.
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included in this review provide more conclusive evidence
on clonally related UTUC and paired UCB.
The order of clinical detection of multiple tumors in vis-
ceral organs is not always in line with the molecular develop-
ment of the tumors. This characteristic has previously been
proposed for multiple metachronous UCB by van Tilborg
et al. [37]. Moreover, clones that derive from a primary
tumor of the upper urinary tract could evolve over time and
develop additional genomic alterations. An IVR derived
from such a clone, however, could be diagnosed prior to the
primary UTUC and molecular analysis of both entities will,
in such cases, reveal more genomic alterations of the IVR in
addition to overlapping mutations. This ‘tumor evolution’
could also apply to the primary UTUC. Therefore, not all
alterations will necessarily be shared by 2 paired tumors due
to evolution of tumors, although a large proportion will. Con-
sequently, a 100% overlap of alterations is rarely present in
clonally related UTUC and paired UCB, as Audenet et al.
demonstrated with an 86% overlap [35]. Therefore, when
analyzing recurrences in the urinary tract and when interpret-
ing a clonal or a nonclonal relationship of both entities, one
should be aware that the clinical order is not necessarily the
molecular order of tumor development [31,37].
The proportion of patients diagnosed with a primary
UCB who later developed a UTUC recurrence might be
overestimated in the studies included. Twelve of the 29
(41.3%) patients analyzed by Audenet et al. had a primary
UCB followed by a diagnosis of UTUC, which is a higher
proportion than that reported in the literature (1%−5%)
[1,17]. Four of these 12 patients, however, showed a
clonal relationship compatible with a previously devel-
oped UTUC instead of a primary UCB, as the UCBs
showed a surplus of alterations compared to the UTUCs.
Therefore, it is possible that the UTUCs originated first
and the UCBs were clones or subclones of the UTUC with
an accumulation of molecular alterations, and had devel-
oped later than the UTUCs.
Whether IVR are formed by seeding/migration of tumor
cells originating from the upper urinary tract or by field can-
cerization remains subject of debate [18−20]. The majority
of patients develop an IVR within 2 years following RNU,
possibly due to manipulation of the tumor during surgery
[11]. This hypothesis of distributing tumor cells by manipu-
lation is further supported by the fact that a diagnostic ure-
terorenoscopy prior to RNU increases the risk of an IVR
[38]. In addition, a systematic review showed that instabil-
ity of the UTUC, defined by presence of necrosis and posi-
tive preoperative urinary cytology, correlated with the risk
of IVR [11]. As we found in the present review that 94% of
the primary UTUC and IVRs were clonally related, we
assume that in primary UTUC patients the most important
mechanism of developing an IVR is seeding or migration of
tumor cells. However, it is not excluded that field canceriza-
tion could contribute to the development of separate entities
of urothelial carcinoma in the upper and lower urinary tract.Analyzing a cohort of 512 UTUCs, Xylinas et al. showed
that smoking was significantly associated with the risk of
an IVR [39]. Du et al. addressed exposure to the Aristolo-
chic Acid (AA) [34], a widely used herb in Chinese medi-
cine, in a Chinese patient cohort and found that all tumors
had predominant T to A transversions in the 5’-CpTpG-
3’motif, which is a mutational signature caused by AA
[40]. The mutagenic aspect of this herb might contribute to
field cancerization in patients and hence to the development
of non-clonally related urothelial tumors. Patients with
Lynch syndrome (LS) have a higher risk of developing
urothelial carcinoma, mainly UTUC [8]. LS is a hereditary
cancer syndrome characterized by mutations in mismatch
repair genes leading to mismatch repair deficiency and
MSI. Possibly, LS could lead to the independent develop-
ment of UTUC and UCB, but literature is lacking on this
matter. One LS patient analyzed by Audenet et al. showed a
clonal relation of paired UTUC and IVR (personal commu-
nication F. Audenet).
Clonality of primary tumors and metachronous or syn-
chronous intracaval recurrences have been analyzed in
malignancies originating from other hollow visceral
organs than the urinary tract, such as the lung, colon, and
oral cavity. LOH analysis and mutational status of EGFR,
TP53, and KRAS in multifocal lung cancer (n = 115)
revealed that 64%−79% of multiple synchronous intrapul-
monary, mostly nonsmall cell carcinomas (NSCLCs),
were clonally related [41−43]. For tumors of the oral cav-
ity, however, it was not clear whether multiple tumors
resulted from field cancerization or intraluminal spread
[44]. With the use of microarray-based SNP and copy-
number genotyping of 104 paired synchronous colorectal
cancers, a clonal relationship was found in 36% [45].
Patients with oligoclonal NSCLCs seemed to have a better
outcome than patients with NSCLCs of monoclonal origin,
which has also been reported for patients with oligoclonal
colorectal tumors [43,45]. These data show that clonality
of paired tumors originating from the same hollow visceral
organ might correspond with clinical outcome. Therefore,
it is of importance to investigate this phenomenon in the
urinary tract by larger, prospective studies.
In case UTUC and IVR are clonally related, the way is
paved for the identification of patient-specific genomic
alterations that can be used to develop noninvasive urine-
based assays for the diagnostic surveillance following
RNU. Cystoscopy, which is invasive and causes discom-
fort to the patient, might be replaced by this alternative
urine-based strategy [46]. Large-scale genomic characteri-
zation of UTUC and paired bladder recurrences could also
identify new biomarkers that correlate with the risk of a
future urinary tract recurrence or clinical outcome and
possibly new actionable molecular alterations. With an
accuracy of only 62% to 69% of 2 previous designed pre-
dictive tools for the risk of IVR development after RNU,
addition of biomarkers might provide a better prediction
of recurrences [47,48].
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Patients diagnosed with an urothelial carcinoma of the
urinary tract are at increased risk of developing a subse-
quent tumor throughout the entire urinary tract. Patients
with a primary UTUC have the highest risk of developing a
future UCB. We systematically reviewed all the relevant lit-
erature to address whether UTUC and paired UCB derive
from the same progenitor cell or whether they develop inde-
pendently as a result of field cancerization. The populations
studied and the molecular techniques used to assess clonal-
ity differed largely between the studies and over time. Tak-
ing into account the limitations of microsatellite instability
technology versus NGS and the currently accepted concepts
of tumor heterogeneity and evolution, we conclude that it is
highly likely that UTUC and paired UCB of one patient are
clonally related and most likely are formed by seeding of
tumor cells.
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